Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 1, 2012, Pages 123-130

  Beazley, Kelly E ^a   Deasey, Stephanie ^a   Lima, Florence ^a   Nurminskaya, Maria V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

catenin; calcification; transglutaminase 2; vascular biology; warfarin

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SIGNAL PEPTIDE; WARFARIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL; BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; ANTICOAGULANTS; BETA CATENIN; CELL LINE; GTP-BINDING PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, CARDIOVASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES; UP-REGULATION; VASCULAR CALCIFICATION; WARFARIN;

EID: 83655167174     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.237834     Document Type: Article

References (62)

1. Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ. Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol. 2011;34:74-81.
2. Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007;20:417-422. (Pubitemid 350081495)
3. Whittaker P, Donovan JL, Przyklenk K. Long-term warfarin therapy is associated with tissue calcification. J Thromb Thrombolysis. 2008; 25:125.
4. Fusaro M, Crepaldi G, Maggi S, D'Angelo A, Calo L, Miozzo D, Fornasieri A, Gallieni M. Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. Curr Vasc Pharmacol 2011;9:763-769.
5. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400-1407. (Pubitemid 28421877)
6. Essalihi R, Dao HH, Yamaguchi N, Moreau P. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. Am J Hypertens. 2003;16:103-110. (Pubitemid 36143427)
7. Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003;40: 531-537. (Pubitemid 38186463)
8. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81. (Pubitemid 27130923)
9. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res. 2006;98: 1024-1031.
10. Rulcova A, Prokopova I, Krausova L, Bitman M, Vrzal R, Dvorak Z, Blahos J, Pavek P. Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drugmetabolizing cytochrome P450 enzymes. J Thromb Haemost. 2010;8: 2708-2717.
11. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005;8:229-231.
12. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006;260:192-210. (Pubitemid 44253633)
13. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99: 1044-1059. (Pubitemid 44729928)
14. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938-2948. (Pubitemid 351787058)
15. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost. 2005;94:780-786. (Pubitemid 41489237)
16. Nurminskaya M, Magee C, Faverman L, Linsenmayer TF. Chondrocytederived transglutaminase promotes maturation of preosteoblasts in periosteal bone. Dev Biol. 2003;263:139-152. (Pubitemid 37268009)
17. Nurminsky D, Shanmugasundaram S, Deasey S, Michaud C, Allen S, Hendig D, Dastjerdi A, Francis-West P, Nurminskaya M. Transglutaminase 2 regulates early chondrogenesis and glycosaminoglycan synthesis. Mech Dev. 2011;128:234-245.
18. Deasey S, Grichenko O, Du S, Nurminskaya M. Characterization of the transglutaminase gene family in zebrafish and in vivo analysis of transglutaminase-dependent bone mineralization. Amino Acids 2011 [Epub ahead of print].
19. Johnson KA, Terkeltaub RA. External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification. J Biol Chem. 2005;280:15004-15012. (Pubitemid 40562853)
20. Al-Jallad HF, Nakano Y, Chen JL, McMillan E, Lefebvre C, Kaartinen MT. Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures. Matrix Biol. 2006;25:135-148.
21. Chabot N, Moreau S, Mulani A, Moreau P, Keillor JW. Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening. Chem Biol. 2010;17:1143-1150.
22. Kaartinen MT, Murshed M, Karsenty G, McKee MD. Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of Matrix Gla protein-deficient mice. J Histochem Cytochem. 2007;55:375-386. (Pubitemid 46481945)
23. Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M. Extracellular transglutaminase 2 activatesβ-catenin signaling in calcifying vascular smooth muscle cells. FEBS Lett. 2008;582:1552-1557.
24. Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res. 2008;102:529-537. (Pubitemid 351416752)
25. Glass DA, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007;148:2630-2634. (Pubitemid 46984774)
26. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210-1220. (Pubitemid 40629039)
27. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
28. Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/β-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010;107:271-282.
29. Trigwell SM, Lynch PT, Griffin M, Hargreaves AJ, Bonner PL. An improved colorimetric assay for the measurement of transglutaminase (type II)-(γ-glutamyl) lysine cross-linking activity. Anal Biochem. 2004; 330:164-166. (Pubitemid 38746988)
30. Kim SY, Park WM, Jung SW, Lee J. Novel transglutaminase inhibitors reduce the cornified cell envelope formation. Biochem Biophys Res Commun. 1997;233:39-44. (Pubitemid 27215905)
31. Price PA, Chan WS, Jolson DM, Williamson MK. The elastic lamellae of devitalized arteries calcify when incubated in serum: evidence for a serum calcification factor. Arterioscler Thromb Vasc Biol. 2006;26:1079-1085. (Pubitemid 43732115)
32. Bouvet C, Moreau S, Blanchette J, de BD, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factorβin arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28: 856-862. (Pubitemid 351544099)
33. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-E17.
34. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867. (Pubitemid 41103395)
35. Prosdocimo DA, Wyler SC, Romani AM, O'Neill WC, Dubyak GR. Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol. 2010;298:C702-C713.
36. Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis. 2011;18:105-112.
37. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-519. (Pubitemid 32728438)
38. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT andβ-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691-701. (Pubitemid 39150127)
39. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733-741.
40. Mikhaylova L, Malmquist J, Nurminskaya M. Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif Tissue Int. 2007;81:372-381. (Pubitemid 50000811)
41. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999;398: 431-436. (Pubitemid 29180376)
42. Watts RE, Siegel M, Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem. 2006;49:7493-7501. (Pubitemid 44913408)
43. Begg GE, Carrington L, Stokes PH, Matthews JM, Wouters MA, Husain A, Lorand L, Iismaa SE, Graham RM. Mechanism of allosteric regulation of transglutaminase 2 by GTP. Proc Natl Acad Sci USA. 2006;103: 19683-19688. (Pubitemid 46037492)
44. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4:140-156. (Pubitemid 36172696)
45. Nurminskaya MV, Recheis B, Nimpf J, Magee C, Linsenmayer TF. Transglutaminase factor XIIIA in the cartilage of developing avian long bones. Dev Dyn. 2002;223:24-32. (Pubitemid 34038796)
46. Goodwin AM, D'Amore PA. Wnt signaling in the vasculature. Angiogenesis. 2002;5:1-9. (Pubitemid 36076918)
47. van Gijn ME, Daemen MJ, Smits JF, Blankesteijn WM. The wnt-frizzled cascade in cardiovascular disease. Cardiovasc Res. 2002;55:16-24. (Pubitemid 34615937)
48. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for theβ-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res. 2002;90:340-347. (Pubitemid 34633936)
49. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res. 2011;109: 564-577.
50. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic Msx2-Wnt calcification cascade is regulated by TNF-α-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol. 2007;27:2589-2596. (Pubitemid 350158910)
51. Dwivedi A, Slater SC, George SJ. MMP-9 and-12 cause N-cadherin shedding and therebyβ-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009;81:178-186.
52. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004; 110:3480-3487. (Pubitemid 39602227)
53. Qin X, Corriere MA, Matrisian LM, Guzman RJ. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol. 2006;26:1510-1516. (Pubitemid 44288976)
54. Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: LDLdensity-pressure theory. J Cell Biochem. 2011;112:2222-2229.
55. Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA. Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem. 2008;283: 20505-20522.
56. Haroon ZA, Wannenburg T, Gupta M, Greenberg CS, Wallin R, Sane DC. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest. 2001;81:83-93. (Pubitemid 32108642)
57. Sumi Y, Inoue N, Azumi H, Seno T, Okuda M, Hirata K, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability. Atherosclerosis. 2002;160:31-39. (Pubitemid 34076643)
58. Boisvert WA, Rose DM, Boullier A, Quehenberger O, Sydlaske A, Johnson KA, Curtiss LK, Terkeltaub R. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler Thromb Vasc Biol. 2006;26:563-569.
59. Matlung HL, VanBavel E, van den Akker J, de Vries CJ, Bakker EN. Role of transglutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice. Atherosclerosis. 2010; 213:77-84.
60. Kodama S, Negishi M. Pregnane X receptor PXR activates the GADD45βgene, eliciting the p38 MAPK signal and cell migration. J Biol Chem. 2011;286:3570-3578.
61. Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108:446-457.
62. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556-563.